Article
Site-specific mutagenesis screening in KRASG12D mutant library to uncover resistance mechanisms to KRASG12D inhibitors.
Cancer letters - 1 Jun 2024
Choi Jeesoo, Shin Ju-Young, Kim Taeyul K, Kim Kiwook, Kim Jiyun, Jeon Eunhye, Park Juyeong, Han Yoon Dae, Kim Kyung-A, Sim Taebo, Kim Hui Kwon, Kim Han Sang
Abstract excerpt
KRAS plays a crucial role in regulating cell survival and proliferation and is one of the most commonly mutated oncogenes in human cancers. The novel KRASG12D inhibitor, MRTX1133, demonstrates promising antitumor efficacy in vitro and in vivo. However, the development of acquired resistance in treated patients presents a considerable challenge to sustained therapeutic effectiveness. In response to this challenge,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.